Mammalian Cell Culture Market Size to Reach USD 8,818.1 Million in 2032
The Mammalian Cell Culture Market size was USD 3,348.6 Million in 2024 and is expected to register a revenue CAGR of 12.8% during the forecast period
18 February, 2025 – Adoption of regenerative medicine development is a key driver driving market revenue growth. The culture of mammalian cells, or, more specifically, the development and spread of cells generated from animal tissues with an adequate surface, nutrients, and environment, is one of the most important model systems for researchers in a variety of domains of biology and medicine.
Regenerative medicine continues to develop and gain popularity. Unlike traditional drugs, cells function as therapeutic active molecules. Regenerative medicine frequently makes use of cells or tissues donated by patients or healthy people. These cells are grown or treated in some other way after being removed from the body. Advances in cell culture technology, such as culture media, vessels, and procedures, have made it possible to reproduce in vitro the features and functions of cells, tissues, and organs. Cultured cells are employed for drug development and regenerative medicine, as well as fundamental biology and molecular biology research.
On April 2022, Sumitomo Chemical Co., Ltd. has inked an equity participation and commercial alliance agreement with Myoridge Co., Ltd., a startup firm spun out of Kyoto University with a diverse spectrum of cell culture technologies. Sumitomo Chemical will increase its efforts to promote the use of regenerative medicine and cell treatment, such as improving quality and lowering production costs for cell products, by combining the technology and resources of both firms.
However, limited scale-up opportunities of mammalian cell bioprocessing systems and concerns regarding contamination of mammalian cell lines acts as challenges for growth of the market. Monoclonal antibodies (MAB) are one of the most important products in the biopharmaceutical business due to its diagnostic and therapeutic applications. However, producing industrial-scale quantities of MAB is an expensive and difficult task. Complications in these systems include the need to grow cultures in complex media, the lack of online measurements for many key substrates, metabolites, and products, the limited and noisy nature of much of the available experimental data, and the extremely complex underlying reaction system.
Key Highlights:
- Equipment segment is expected to register the largest market share over the forecast period. The ideal animal cell culture laboratory should include equipment such as a laminar hood, CO2 incubator, inverted microscope, autoclave, and centrifuge. Ice crystal formation, changes in electrolyte content, dehydration, and pH fluctuations can all induce cell death. For this reason, cells must be stored at extremely low temperatures (-180°C to -196°C). Since less ice crystals form below -130°C, liquid nitrogen is utilized to freeze cells at low temperatures. Glycerol or Dimethyl Sulfoxide (DMSO), which are cryoprotective compounds, are used to counteract the effects of freezing.
- Drug screening and development segment is expected to account for the fastest growth rate over the forecast period. Biopharmaceuticals are a rapidly increasing segment of the pharmaceutical industry, with applications ranging from oncology to rheumatology. Cultured mammalian cells have become the most common expression system for drug manufacture, because of their ability to complete the posttranslational changes essential for medication safety and efficacy. Over the last decade, productivity in mammalian cell culture production procedures has increased considerably due to increases in both volumetric and specific productivities.
- North America accounted for largest market revenue share in the mammalian cell culture market in 2024 due to the technological advancements in mammalian cell culture technologies and increase in demand for biologics. On May 2022, Avance Biosciences, a leading CRO that provides GLP/GMP-compliant assay development, assay validation, and sample testing services to support biological drug development and manufacturing, has announced the completion of the move-in and validation of an additional 26,000 square feet of laboratory space acquired in the previous year. Avance also announced an expansion of validated protein and cell-based assay services to serve biopharma and CDMO clients with therapeutic biologic discovery, development, and regulatory filings.
- Some major companies in the market report include Merck KGaA, Cytiva, Thermo Fisher Scientific, Fujifilm Irvine Scientific, Novartis AG, Agilent Technologies, Inc., Lonza Group AG, Corning Inc., Horizon Discovery Ltd., Promocell GmbH, HiMedia Laboratories Private Limited, BD Biosciences, STEMCELL Technologies, and Cell Culture Company, LLC.
- On June 2024, Predictive Oncology Inc., a pioneer in AI-driven drug discovery and biologics, has released its novel 3D cell culture model to accelerate cancer medication discovery and future drug development. Organ-specific 3D cell cultures better match human tissue architecture than typical 2D experiments, making them a more realistic tool for in vivo drug candidate clinical testing. This enables more accurate projections of clinical outcomes and can be used to optimize candidate selection for future clinical development.
- On November 2023, Mytos, an innovative pioneer in automated cell production, announced that it has secured USD 19 million in Series A funding headed by Buckley Ventures, with participation from IQ Capital and Wing VC. To satisfy rising demand, the money will speed up the manufacture and distribution of Mytos’ automated cell production technology to more biotech and pharmaceutical companies. The platform is already being used by several life sciences companies worldwide. Mytos also intends to grow its sales and development team.
Unlock the key to transforming your business strategy with our Mammalian Cell Culture Market insights –
Navistrat Analytics has segmented mammalian cell culture market based on product, application, and end-use:
- Product Outlook (Revenue, USD Million; 2022-2032)
- Consumables
- Media
- Serum-Free Media
- Serum-Containing Media
- Protein-Free Media
- Specialty Media
- Reagents
- Growth Factors
- Amino Acids
- Buffers
- Supplements
- Others
- Media
- Consumables
-
- Equipment
- Bioreactors
- Single-Use Bioreactors
- Multi-Use Bioreactors
- Storage
- Refrigerators and Freezers
- Cryostorage Systems
- Centrifuges
- Filtration Systems
- Cell Culture Vessels
- Others
- Bioreactors
- Equipment
- Application Outlook (Revenue, USD Million; 2022-2032)
- Diagnostics
- Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccines Production
- Others
- Tissue Culture & Engineering
- Cell & Gene Therapy
- Drug Screening and Development
- Toxicity Testing
- Others
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Pharmaceutical & Biotechnology Companies
- Hospitals And Diagnostic Laboratories
- Research & Academic Institutes
- Contract Research Organizations (CROs)
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America